Sector
PharmaceuticalsOpen
₹27.13Prev. Close
₹27Turnover(Lac.)
₹0.1Day's High
₹27.13Day's Low
₹25.6552 Week's High
₹62.7552 Week's Low
₹21.03Book Value
₹56.15Face Value
₹10Mkt Cap (₹ Cr.)
33.95P/E
0EPS
0Divi. Yield
0Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 13.42 | 17.75 | 15.06 | 6.63 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 63.65 | 67.79 | 68.42 | 34.72 |
Net Worth | 77.07 | 85.54 | 83.48 | 41.35 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
---|---|---|---|---|
Revenue | 154.37 | 126.83 | 121.69 | 76.04 |
yoy growth (%) | 21.72 | 4.21 | 60.03 | 12.37 |
Raw materials | -103.96 | -88.96 | -87.84 | -52.89 |
As % of sales | 67.34 | 70.14 | 72.17 | 69.55 |
Employee costs | -13.67 | -7.93 | -6.39 | -5.64 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
---|---|---|---|---|
Profit before tax | 10.13 | 8.4 | 8.1 | 4.95 |
Depreciation | -1.31 | -1.22 | -1.12 | -1.19 |
Tax paid | -3.11 | -2.31 | -2.45 | -1.22 |
Working capital | 19.15 | 4.18 | 12.01 | 8.57 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 21.72 | 4.21 | 60.03 | 12.37 |
Op profit growth | 14.75 | 6.52 | 61.15 | 12.43 |
EBIT growth | 16.24 | 7.86 | 59.96 | 22.36 |
Net profit growth | 15.28 | 7.9 | 51.68 | 31.89 |
Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Gross Sales | 146.11 | 219.89 | 354.3 | 154.38 |
Excise Duty | 0 | 0 | 0 | 0 |
Net Sales | 146.11 | 219.89 | 354.3 | 154.38 |
Other Operating Income | 0 | 0 | 0 | 0 |
Other Income | 0.7 | 9.72 | 0.9 | 0.56 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,766.2 | 134.52 | 4,23,770.54 | 1,181.05 | 0.76 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,958.35 | 76.3 | 1,58,175.47 | 594 | 0.5 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,486.75 | 25.8 | 1,20,075.94 | 1,438.15 | 0.87 | 4,134.87 | 360.72 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,183 | 59.05 | 1,07,722.35 | 485 | 0.88 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,434.1 | 51.93 | 1,00,425.74 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Managing Director
Rajesh Gupta
Whole Time Director & CFO
Saruchi Gupta
Independent Director
Sukhpal Singh
Independent Director
Chetna
Company Sec. & Compli. Officer
Harshita Aggarwal
Non Executive Director
Rohit Mittal
Independent Director
Harvinder Singh Dhami
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by ANG Lifesciences India Ltd
Summary
ANG Lifesciences India Limited was originally incorporated as a Private Limited Company with the name ANG Lifesciences India Private Limited on June 14, 2006. On conversion into Public Limited Company, the name was changed to ANG Lifesciences India Limited on March 02, 2010. The Company further converted into Private Limited Company and the name of the Company was changed to ANG Lifesciences India Private Limited on September 22, 2010. Subsequently, on conversion into Public Limited Company, the name again changed to ANG Lifesciences India Limited on May 18, 2016.The Company is engaged in the business of manufacturing and marketing of finished pharmaceutical formulation in the form of Sterile Dry Powder Injection Vials. In 2008-09, the Company started its commercial production. In 2014-15, it commenced direct sale of medicines covering hospitals , Doctors through stockists. The Company is ISO-9001:2008 certified, which manufacture its products in compliance with GMP requirements. Company has dedicated area, machinery, facilities and advanced equipment for manufacturing of Beta Lactum & Non Beta Lactum products as per GMP norms. The Company currently operates a strong manufacturing set-up consisting of 4 formulation plants situated at Baddi, Himachal Pradesh. These state-of-art facilities have integrated process development teams with in-house engineering capabilities and well equipped with quality control laboratories with most modern and validate analytical equipment. It al
Read More
The ANG Lifesciences India Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is ₹26 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of ANG Lifesciences India Ltd is ₹33.95 Cr. as of 09 May ‘25
The PE and PB ratios of ANG Lifesciences India Ltd is 0 and 0.48 as of 09 May ‘25
The 52-week high/low is the highest and lowest price at which a ANG Lifesciences India Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of ANG Lifesciences India Ltd is ₹21.03 and ₹62.75 as of 09 May ‘25
ANG Lifesciences India Ltd's CAGR for 5 Years at 11.03%, 3 Years at -46.51%, 1 Year at -51.38%, 6 Month at -39.93%, 3 Month at -31.21% and 1 Month at -6.44%.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.